125 related articles for article (PubMed ID: 11313781)
1. Sustained expression of human apo A-I following adenoviral gene transfer in mice.
De Geest B; Van Linthout S; Collen D
Gene Ther; 2001 Jan; 8(2):121-7. PubMed ID: 11313781
[TBL] [Abstract][Full Text] [Related]
2. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
3. Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I.
Van Linthout S; Collen D; De Geest B
Hum Gene Ther; 2002 May; 13(7):829-40. PubMed ID: 11975849
[TBL] [Abstract][Full Text] [Related]
4. The impact of antigen expression in antigen-presenting cells on humoral immune responses against the transgene product.
Feng Y; Jacobs F; Van Craeyveld E; Lievens J; Snoeys J; Van Linthout S; De Geest B
Gene Ther; 2010 Feb; 17(2):288-93. PubMed ID: 19759564
[TBL] [Abstract][Full Text] [Related]
5. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer.
De Geest B; Van Linthout S; Lox M; Collen D; Holvoet P
Hum Gene Ther; 2000 Jan; 11(1):101-12. PubMed ID: 10646643
[TBL] [Abstract][Full Text] [Related]
6. Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer.
Snoeys J; Mertens G; Lievens J; van Berkel T; Collen D; Biessen EA; De Geest B
Mol Ther; 2006 Jan; 13(1):98-107. PubMed ID: 16112619
[TBL] [Abstract][Full Text] [Related]
7. [Hydrodynamics-based transfer of human apolipoprotein A-I gene into mice: study of factors involving an efficacy and duration of the transferred gene expression in animals' liver].
Ajuf'ev BN; Dizhe EB; Efremov AM; Mogilenko DA; Oleĭnikova GN; Lapikov IA; Zhdanova OIu; Kidgotko OV; Orlov SV; Perevozchikov AP
Mol Biol (Mosk); 2004; 38(6):1076-84. PubMed ID: 15612596
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer.
Jacobs F; Snoeys J; Feng Y; Van Craeyveld E; Lievens J; Armentano D; Cheng SH; De Geest B
Gene Ther; 2008 Apr; 15(8):594-603. PubMed ID: 18288213
[TBL] [Abstract][Full Text] [Related]
9. Muscle stem cells can act as antigen-presenting cells: implication for gene therapy.
Cao B; Bruder J; Kovesdi I; Huard J
Gene Ther; 2004 Sep; 11(17):1321-30. PubMed ID: 15175641
[TBL] [Abstract][Full Text] [Related]
10. Strain-specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1(-), E2b(-)] adenoviral vectors.
Everett RS; Evans HK; Hodges BL; Ding EY; Serra DM; Amalfitano A
Virology; 2004 Jul; 325(1):96-105. PubMed ID: 15231389
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells.
De Geest BR; Van Linthout SA; Collen D
Blood; 2003 Apr; 101(7):2551-6. PubMed ID: 12446451
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression.
Michou AI; Santoro L; Christ M; Julliard V; Pavirani A; Mehtali M
Gene Ther; 1997 May; 4(5):473-82. PubMed ID: 9274725
[TBL] [Abstract][Full Text] [Related]
13. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter.
Gill DR; Smyth SE; Goddard CA; Pringle IA; Higgins CF; Colledge WH; Hyde SC
Gene Ther; 2001 Oct; 8(20):1539-46. PubMed ID: 11704814
[TBL] [Abstract][Full Text] [Related]
14. Promoters influence the kinetics of transgene expression following adenovector gene delivery.
Chen P; Tian J; Kovesdi I; Bruder JT
J Gene Med; 2008 Feb; 10(2):123-31. PubMed ID: 18064718
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
16. TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression.
Sung RS; Qin L; Bromberg JS
Mol Ther; 2001 May; 3(5 Pt 1):757-67. PubMed ID: 11356080
[TBL] [Abstract][Full Text] [Related]
17. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains.
Barr D; Tubb J; Ferguson D; Scaria A; Lieber A; Wilson C; Perkins J; Kay MA
Gene Ther; 1995 Mar; 2(2):151-5. PubMed ID: 7719932
[TBL] [Abstract][Full Text] [Related]
18. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity.
Gu J; Andreeff M; Roth JA; Fang B
Gene Ther; 2002 Jan; 9(1):30-7. PubMed ID: 11850720
[TBL] [Abstract][Full Text] [Related]
19. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.
Yew NS; Przybylska M; Ziegler RJ; Liu D; Cheng SH
Mol Ther; 2001 Jul; 4(1):75-82. PubMed ID: 11472109
[TBL] [Abstract][Full Text] [Related]
20. Activator protein 1-mediated transcriptional regulation strategy sustains long-term expression of a xenogeneic gene product in vivo: an implication for gene therapy targeting congenital protein deficiencies.
Sasaki S; Smith JM; Takase K; Okuda K; Ishii N; Takeshita F
Int J Mol Med; 2006 Aug; 18(2):289-97. PubMed ID: 16820937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
